UNSPSC 51172005: Fencibutirol

This classification denotes a cholagogue or choleretic agent with the molecular formula C16H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H2V165956A, chemically known as cyclohexaneacetic acid, alpha-ethyl-1-hydroxy-4-phenyl-, (+-)- but generally known as fencibutirol, which bears US NIH Compound Identifier 71170. European Medicines Agency schedules Fencibutirol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07547MIG.

UNSPSC 51172005 Fencibutirol is a Commodity code that maps to state and local procurement of drug testing services, specifically offender specimen collection, immunoassay and confirmatory testing (LC/MS/MS or GC/MS), and alternative methodologies including oral fluid and hair analysis. State and local issuing bodies under this code include county community supervision and corrections departments and related criminal justice agencies responsible for monitoring and testing of probationers, parolees, and other offenders. The work encompasses staffing on-site collection facilities, operating automated testing notification systems, managing specimen logistics, maintaining SAMHSA, state DPS, or CAP lab certifications, and delivering electronic result reporting. Vendors must price services on a per-test basis across multiple service models (screening only, screening with confirmation, or automatic confirmation of positives) with all-inclusive pricing that absorbs freight, delivery, insurance, and staffing costs.

Collin County Community Supervision and Corrections Department in Texas has posted RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026. The county operates two collection sites in Plano and McKinney during business hours plus five Saturdays annually, with an estimated annual testing volume of approximately 25,031 tests across five-panel and six-panel screens plus ancillary testing. The contract value is estimated at $600,000 over an initial two-year term commencing September 1, 2026, with three optional one-year renewals not to exceed five years total. Price redetermination is limited to annual adjustment based on medical Consumer Price Index increases capped at 3.0 percent. Evaluation criteria include vendor understanding and qualifications (55 points combined), client references (15 points), cost (30 points), and optional Phase 2 demonstrations and interviews (up to 30 points). The anticipated award date is August 10, 2026, with funding from the Texas Department of Criminal Justice-Community Justice Assistance Division.